

RECEIVED  
CENTRAL FAX CENTER

MAR 25 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

**PATENT**  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 10/815,353 Issued as U.S. Patent No. 6,808,712 (the "712 PATENT")

RECEIVED  
CENTRAL FAX CENTER

NO.343

P.4

MAR '2 5 2005

Phareby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Anthony Bar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "'849 PATENT")
2. Application No. 09/724,102 Issued as U.S. Patent No. 6,787,139 (the "'139 PATENT")

PAGE 4/5 \* RCVD AT 3/25/2005 11:54:05 AM [Eastern Standard Time] \* SVR:USPTO-EFXXF-1/1 \* DMS:0729306 \* CSD:16503262422 \* DURATION (mm:ss):02:02

03/28/2005 HVILLARI 00000010 201430 10815391

02 FC:1814 130.00 DA

RECEIVED  
CENTRAL FAX CENTER

NO.342 P.4/6

MAR 25 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Anthony B...

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 09/724,489 Issued as U.S. Patent No. 6,787,140 (the "140 PATENT")

PAGE 4/8 \* RCVD AT 3/25/2005 11:51:09 AM [Eastern Standard Time] \* SVR:USPTO-EFXXF-1/0 \* DNS:8729306 \* CSID:16503262422 \* DURATION (mm-ss):01-48

03/28/2005 NVILLARI 00000010 201430 10815391

01 FC:1814 130.00 DA

RECEIVED  
CENTRAL FAX CENTER

NO. 345 P. 4/6

MAR 25 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 09/201,430 Issued as U.S. Patent No. 6,787,523 (the "523 PATENT")

RECEIVED  
CENTRAL FAX CENTER

MAR 25 2005

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNER") and attorney of record in the above-identified patent application. ASSIGNER is the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 09/723,762 Issued as U.S. Patent No. 6,787,144 (the "144 PATENT")

RECEIVED  
CENTRAL FAX CENTER


MAR 25 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

March 25, 2005.

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "'849 PATENT")
2. Application No. 09/723,927 Issued as U.S. Patent No. 6,787,138 (the "'138 PATENT")

RECEIVED  
CENTRAL FAX CENTER

MAR 25 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 10/816,022 Issued as U.S. Patent No. 6,866,850 (the "850 PATENT")

PAGE 4/8 \* RCVD AT 3/25/2005 12:05:31 PM [Eastern Standard Time] \* SVR:USPTO-EFAXF-1H \* DNS:8729306 \* CSID:16503262422 \* DURATION (mm:ss):01:54

RECEIVED  
CENTRAL FAX CENTER

MAR 25 2005

I hereby certify that this correspondence is being facsimile  
transmitted to the U.S. Patent and Trademark Office, Fax  
No. 1-703-872-9306 on

PATENT  
Attorney Docket No.: 15270J-4729US  
Client Ref. No.: 209-US-CIP4C4

March 25, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Anthony Ben

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SCHENK, Dale B.

Application No.: 10/815,391

Filed: March 31, 2004

Patent No.: 6,866,849

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Soheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter  
"ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is  
the assignee of total interest of:

1. Application No. 10/815,391 Issued as U.S. Patent No. 6,866,849 (the "849 PATENT")
2. Application No. 09/724,477 Issued as U.S. Patent No. 6,787,143 (the "143 PATENT")

PAGE 4/6 \* RCVD AT 3/25/2005 11:47:50 AM [Eastern Standard Time] \* SVR:USPTO-EFXXF-1/1 \* DUS:8729303 \* CSID:16503262422 \* DURATION (mm:ss):02:02

03/28/2005 NVILLARI 00000005 201430 10815391

01 FC:1814 130.00 DA